Share Price and Basic Stock Data
Last Updated: February 3, 2026, 2:01 am
| PEG Ratio | 0.22 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Brooks Laboratories Ltd operates in the pharmaceuticals sector and has shown a significant fluctuation in revenue over recent quarters. For the quarter ending September 2023, the company reported sales of ₹24.32 Cr, a notable increase from ₹15.70 Cr in the previous quarter (June 2023). However, sales dipped to ₹12.61 Cr by March 2023, indicating volatility in revenue generation. On an annualized basis, the total sales for the fiscal year ending March 2025 stood at ₹83 Cr, slightly up from ₹79 Cr in the previous fiscal year. The trailing twelve months (TTM) sales reached ₹93 Cr, suggesting some recovery. The company’s ability to increase sales in the latter half of 2023, particularly with a jump to ₹21.75 Cr in December 2023, indicates a potentially positive trend, but the overall performance remains inconsistent, reflecting challenges in maintaining stable revenue streams.
Profitability and Efficiency Metrics
Profitability metrics for Brooks Laboratories Ltd reveal significant challenges. The company reported a negative operating profit margin (OPM) of 10.75% for the fiscal year ending March 2025, improved from previous years but still indicative of ongoing operational inefficiencies. The net profit for the same year was ₹14 Cr, a stark contrast to the losses recorded in previous years, such as a net loss of ₹31 Cr in March 2023. The interest coverage ratio (ICR) stood at 5.66x, suggesting that the company is capable of covering its interest obligations, albeit from a low base. The cash conversion cycle (CCC) was reported at 58.54 days, which is relatively high and indicates potential inefficiencies in managing working capital. Overall, while there are signs of recovery, the company must address its profitability issues to sustain long-term growth.
Balance Sheet Strength and Financial Ratios
Brooks Laboratories Ltd’s balance sheet presents a mixed picture. As of March 2025, total assets were valued at ₹124 Cr, with total liabilities at ₹90 Cr, leading to a manageable debt-to-equity ratio of 0.06, indicating low leverage. The company has reserves amounting to ₹86 Cr, reflecting a solid equity position. The price-to-book value (P/BV) ratio stood at 3.23x, suggesting that the stock may be overvalued compared to its book value, which was ₹33.30 per share. The return on equity (ROE) was reported at 12.2%, which is within acceptable limits but still lower than many industry peers. Furthermore, with a current ratio of 1.48, Brooks Laboratories appears capable of covering its short-term liabilities. However, the company must focus on enhancing its operational efficiencies to leverage its equity and asset base more effectively.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Brooks Laboratories Ltd indicates a strong promoter presence, holding 52.62% of the company as of March 2025. This represents a decline from previous years when promoter holdings were as high as 66.41%. Institutional investors, including domestic institutional investors (DIIs) who hold 10.38%, have increased their stake, reflecting growing confidence in the company’s recovery. However, foreign institutional investors (FIIs) have minimal involvement, standing at just 0.01%, which may indicate a hesitation among international investors regarding the company’s growth prospects. The number of shareholders decreased to 10,078 by September 2025, suggesting a potential decline in retail investor interest. This mixed sentiment could impact the stock’s liquidity and investor confidence going forward, necessitating efforts to improve transparency and performance.
Outlook, Risks, and Final Insight
Looking ahead, Brooks Laboratories Ltd faces both opportunities and challenges. The recent uptick in sales and reduction in net losses may signal a turning point; however, the company must address its operational inefficiencies and improve profitability metrics to sustain this momentum. Risks include the volatility in sales and the high cash conversion cycle, which could impede cash flow and operational stability. The pharmaceutical sector is competitive, and Brooks Laboratories must innovate and adapt to market demands to enhance its market position. The significant promoter holding suggests potential stability, but the declining percentage may raise concerns about long-term commitment. In conclusion, while there are signs of recovery, the company must strategically navigate its challenges to build a more resilient financial future.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 122 Cr. | 97.0 | 193/84.3 | 27.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,473 Cr. | 319 | 479/192 | 71.9 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.9 Cr. | 44.3 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 73.2 Cr. | 50.0 | 50.0/17.0 | 174 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,464.08 Cr | 1,084.45 | 46.05 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 18.08 | 15.30 | 12.61 | 15.70 | 24.32 | 21.75 | 17.72 | 17.93 | 20.79 | 20.52 | 23.32 | 25.51 | 23.45 |
| Expenses | 27.30 | 23.85 | 16.31 | 19.61 | 25.42 | 25.12 | 27.25 | 19.85 | 24.20 | 22.02 | 24.58 | 22.38 | 20.93 |
| Operating Profit | -9.22 | -8.55 | -3.70 | -3.91 | -1.10 | -3.37 | -9.53 | -1.92 | -3.41 | -1.50 | -1.26 | 3.13 | 2.52 |
| OPM % | -51.00% | -55.88% | -29.34% | -24.90% | -4.52% | -15.49% | -53.78% | -10.71% | -16.40% | -7.31% | -5.40% | 12.27% | 10.75% |
| Other Income | 0.40 | 0.45 | 0.03 | 0.05 | 0.09 | 0.16 | 0.65 | 0.07 | 0.20 | 0.03 | 0.62 | 7.15 | 6.13 |
| Interest | 0.63 | 0.75 | 0.18 | 0.17 | 0.19 | 0.21 | 0.27 | 0.16 | 0.32 | 0.28 | 0.26 | 0.30 | 0.28 |
| Depreciation | 2.28 | 2.33 | 0.44 | 0.44 | 0.44 | 0.43 | 0.46 | 0.40 | 0.43 | 0.38 | 0.39 | 0.39 | 0.39 |
| Profit before tax | -11.73 | -11.18 | -4.29 | -4.47 | -1.64 | -3.85 | -9.61 | -2.41 | -3.96 | -2.13 | -1.29 | 9.59 | 7.98 |
| Tax % | -32.82% | -15.21% | 0.00% | 0.00% | 0.00% | 0.78% | 0.00% | 0.00% | 0.00% | 0.00% | 13.95% | 0.00% | 0.00% |
| Net Profit | -7.87 | -9.48 | -4.29 | -4.47 | -1.64 | -3.88 | -9.61 | -2.41 | -3.96 | -2.13 | -1.46 | 9.58 | 7.98 |
| EPS in Rs | -1.79 | -1.92 | -1.64 | -1.71 | -0.62 | -1.48 | -3.66 | -0.92 | -1.51 | -0.81 | -0.50 | 3.25 | 2.71 |
Last Updated: January 2, 2026, 4:29 am
Below is a detailed analysis of the quarterly data for Brooks Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 23.45 Cr.. The value appears to be declining and may need further review. It has decreased from 25.51 Cr. (Jun 2025) to 23.45 Cr., marking a decrease of 2.06 Cr..
- For Expenses, as of Sep 2025, the value is 20.93 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 22.38 Cr. (Jun 2025) to 20.93 Cr., marking a decrease of 1.45 Cr..
- For Operating Profit, as of Sep 2025, the value is 2.52 Cr.. The value appears to be declining and may need further review. It has decreased from 3.13 Cr. (Jun 2025) to 2.52 Cr., marking a decrease of 0.61 Cr..
- For OPM %, as of Sep 2025, the value is 10.75%. The value appears to be declining and may need further review. It has decreased from 12.27% (Jun 2025) to 10.75%, marking a decrease of 1.52%.
- For Other Income, as of Sep 2025, the value is 6.13 Cr.. The value appears to be declining and may need further review. It has decreased from 7.15 Cr. (Jun 2025) to 6.13 Cr., marking a decrease of 1.02 Cr..
- For Interest, as of Sep 2025, the value is 0.28 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.30 Cr. (Jun 2025) to 0.28 Cr., marking a decrease of 0.02 Cr..
- For Depreciation, as of Sep 2025, the value is 0.39 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.39 Cr..
- For Profit before tax, as of Sep 2025, the value is 7.98 Cr.. The value appears to be declining and may need further review. It has decreased from 9.59 Cr. (Jun 2025) to 7.98 Cr., marking a decrease of 1.61 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is 7.98 Cr.. The value appears to be declining and may need further review. It has decreased from 9.58 Cr. (Jun 2025) to 7.98 Cr., marking a decrease of 1.60 Cr..
- For EPS in Rs, as of Sep 2025, the value is 2.71. The value appears to be declining and may need further review. It has decreased from 3.25 (Jun 2025) to 2.71, marking a decrease of 0.54.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:32 am
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Sales | 77 | 91 | 63 | 79 | 83 | 93 |
| Expenses | 77 | 105 | 93 | 97 | 91 | 90 |
| Operating Profit | 1 | -14 | -30 | -18 | -8 | 3 |
| OPM % | 1% | -16% | -47% | -22% | -10% | 3% |
| Other Income | 1 | 1 | 1 | 1 | 1 | 14 |
| Interest | 3 | 3 | 2 | 1 | 1 | 1 |
| Depreciation | 7 | 7 | 7 | 2 | 2 | 2 |
| Profit before tax | -9 | -24 | -38 | -20 | -10 | 14 |
| Tax % | 115% | -19% | -19% | 0% | 2% | |
| Net Profit | -19 | -19 | -31 | -20 | -10 | 14 |
| EPS in Rs | -7.40 | -4.31 | -7.97 | -7.46 | -3.38 | 4.65 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% |
YoY Net Profit Growth
| Year | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -63.16% | 35.48% | 50.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -63.16% | 98.64% | 14.52% |
Brooks Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 4 years from 2021-2022 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -3% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 4% |
| TTM: | 112% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 30% |
| 3 Years: | 3% |
| 1 Year: | 18% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -22% |
| Last Year: | -12% |
Last Updated: September 5, 2025, 1:25 am
Balance Sheet
Last Updated: December 4, 2025, 1:04 am
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 26 | 29 | 29 |
| Reserves | 54 | 63 | 49 | 39 | 69 | 86 |
| Borrowings | 31 | 25 | 7 | 6 | 8 | 8 |
| Other Liabilities | 52 | 83 | 29 | 19 | 18 | 16 |
| Total Liabilities | 162 | 196 | 110 | 90 | 124 | 140 |
| Fixed Assets | 108 | 110 | 15 | 14 | 14 | 13 |
| CWIP | 1 | 15 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 64 | 43 | 74 | 86 |
| Other Assets | 54 | 71 | 31 | 34 | 36 | 40 |
| Total Assets | 162 | 196 | 110 | 90 | 124 | 140 |
Below is a detailed analysis of the balance sheet data for Brooks Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 29.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 29.00 Cr..
- For Reserves, as of Sep 2025, the value is 86.00 Cr.. The value appears strong and on an upward trend. It has increased from 69.00 Cr. (Mar 2025) to 86.00 Cr., marking an increase of 17.00 Cr..
- For Borrowings, as of Sep 2025, the value is 8.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 8.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 16.00 Cr.. The value appears to be improving (decreasing). It has decreased from 18.00 Cr. (Mar 2025) to 16.00 Cr., marking a decrease of 2.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 140.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 124.00 Cr. (Mar 2025) to 140.00 Cr., marking an increase of 16.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14.00 Cr. (Mar 2025) to 13.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 86.00 Cr.. The value appears strong and on an upward trend. It has increased from 74.00 Cr. (Mar 2025) to 86.00 Cr., marking an increase of 12.00 Cr..
- For Other Assets, as of Sep 2025, the value is 40.00 Cr.. The value appears strong and on an upward trend. It has increased from 36.00 Cr. (Mar 2025) to 40.00 Cr., marking an increase of 4.00 Cr..
- For Total Assets, as of Sep 2025, the value is 140.00 Cr.. The value appears strong and on an upward trend. It has increased from 124.00 Cr. (Mar 2025) to 140.00 Cr., marking an increase of 16.00 Cr..
Notably, the Reserves (86.00 Cr.) exceed the Borrowings (8.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Free Cash Flow | -30.00 | -39.00 | -37.00 | -24.00 | -16.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debtor Days | 64.73 | 70.69 | 73.64 | 74.94 | 88.38 |
| Inventory Days | 177.86 | 156.51 | 79.89 | 60.49 | 62.10 |
| Days Payable | 233.26 | 159.24 | 165.21 | 97.25 | 91.94 |
| Cash Conversion Cycle | 9.34 | 67.96 | -11.69 | 38.18 | 58.54 |
| Working Capital Days | -84.81 | 33.99 | -37.48 | 33.57 | 43.28 |
| ROCE % | -15.50% | -30.45% | -24.70% | -9.90% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Business Cycle Fund | 528,937 | 0.84 | 6.69 | 528,937 | 2025-04-22 17:25:39 | 0% |
| Quant Healthcare Fund | 276,708 | 1.99 | 3.5 | 276,708 | 2025-04-22 17:25:39 | 0% |
| Quant Small Cap Fund | 187,346 | 0.02 | 2.37 | 187,346 | 2025-04-22 17:25:39 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -3.72 | -7.65 | -12.57 | -7.82 | -7.84 |
| Diluted EPS (Rs.) | -3.72 | -7.65 | -12.57 | -7.82 | -7.84 |
| Cash EPS (Rs.) | 1.57 | 1.26 | -8.39 | -4.84 | -4.95 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 33.30 | 24.99 | 29.94 | 54.37 | 32.04 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 33.30 | 24.99 | 29.94 | 54.37 | 32.04 |
| Revenue From Operations / Share (Rs.) | 28.03 | 30.28 | 25.59 | 36.87 | 31.27 |
| PBDIT / Share (Rs.) | 1.98 | 1.59 | -10.61 | -5.44 | 0.50 |
| PBIT / Share (Rs.) | 1.43 | 0.91 | -13.46 | -8.42 | -2.38 |
| PBT / Share (Rs.) | 1.08 | 0.59 | -14.20 | -9.67 | -3.64 |
| Net Profit / Share (Rs.) | 1.02 | 0.58 | -11.23 | -7.82 | -7.84 |
| NP After MI And SOA / Share (Rs.) | -3.38 | -7.46 | -8.46 | -6.55 | -7.84 |
| PBDIT Margin (%) | 7.05 | 5.24 | -41.47 | -14.76 | 1.62 |
| PBIT Margin (%) | 5.11 | 3.01 | -52.59 | -22.83 | -7.62 |
| PBT Margin (%) | 3.86 | 1.95 | -55.48 | -26.23 | -11.63 |
| Net Profit Margin (%) | 3.65 | 1.92 | -43.89 | -21.20 | -25.07 |
| NP After MI And SOA Margin (%) | -12.07 | -24.64 | -33.06 | -17.77 | -25.08 |
| Return on Networth / Equity (%) | -10.15 | -29.87 | -28.26 | -25.67 | -24.47 |
| Return on Capital Employeed (%) | 4.18 | 3.56 | -43.41 | -14.14 | -5.98 |
| Return On Assets (%) | -8.05 | -21.66 | -19.06 | -8.26 | -11.95 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.14 | 0.18 |
| Total Debt / Equity (X) | 0.06 | 0.07 | 0.07 | 0.38 | 0.35 |
| Asset Turnover Ratio (%) | 0.77 | 0.79 | 0.41 | 0.57 | 0.00 |
| Current Ratio (X) | 1.48 | 1.35 | 0.83 | 1.25 | 0.78 |
| Quick Ratio (X) | 1.08 | 0.93 | 0.49 | 0.68 | 0.41 |
| Inventory Turnover Ratio (X) | 8.78 | 4.28 | 2.14 | 2.31 | 0.00 |
| Interest Coverage Ratio (X) | 5.66 | 4.94 | -12.01 | -4.34 | 0.40 |
| Interest Coverage Ratio (Post Tax) (X) | 3.93 | 2.81 | -11.87 | -5.24 | -5.25 |
| Enterprise Value (Cr.) | 322.19 | 247.92 | 159.23 | 271.01 | 179.90 |
| EV / Net Operating Revenue (X) | 3.90 | 3.12 | 2.52 | 2.98 | 2.33 |
| EV / EBITDA (X) | 55.34 | 59.41 | -6.07 | -20.15 | 143.19 |
| MarketCap / Net Operating Revenue (X) | 3.84 | 3.06 | 2.45 | 1.97 | 1.99 |
| Price / BV (X) | 3.23 | 3.71 | 2.09 | 2.84 | 1.94 |
| Price / Net Operating Revenue (X) | 3.84 | 3.06 | 2.45 | 1.97 | 1.99 |
| EarningsYield | -0.03 | -0.08 | -0.13 | -0.09 | -0.12 |
After reviewing the key financial ratios for Brooks Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -3.72. This value is below the healthy minimum of 5. It has increased from -7.65 (Mar 24) to -3.72, marking an increase of 3.93.
- For Diluted EPS (Rs.), as of Mar 25, the value is -3.72. This value is below the healthy minimum of 5. It has increased from -7.65 (Mar 24) to -3.72, marking an increase of 3.93.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.57. This value is below the healthy minimum of 3. It has increased from 1.26 (Mar 24) to 1.57, marking an increase of 0.31.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.30. It has increased from 24.99 (Mar 24) to 33.30, marking an increase of 8.31.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 33.30. It has increased from 24.99 (Mar 24) to 33.30, marking an increase of 8.31.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 28.03. It has decreased from 30.28 (Mar 24) to 28.03, marking a decrease of 2.25.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.98. This value is below the healthy minimum of 2. It has increased from 1.59 (Mar 24) to 1.98, marking an increase of 0.39.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.43. This value is within the healthy range. It has increased from 0.91 (Mar 24) to 1.43, marking an increase of 0.52.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.08. This value is within the healthy range. It has increased from 0.59 (Mar 24) to 1.08, marking an increase of 0.49.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.02. This value is below the healthy minimum of 2. It has increased from 0.58 (Mar 24) to 1.02, marking an increase of 0.44.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -3.38. This value is below the healthy minimum of 2. It has increased from -7.46 (Mar 24) to -3.38, marking an increase of 4.08.
- For PBDIT Margin (%), as of Mar 25, the value is 7.05. This value is below the healthy minimum of 10. It has increased from 5.24 (Mar 24) to 7.05, marking an increase of 1.81.
- For PBIT Margin (%), as of Mar 25, the value is 5.11. This value is below the healthy minimum of 10. It has increased from 3.01 (Mar 24) to 5.11, marking an increase of 2.10.
- For PBT Margin (%), as of Mar 25, the value is 3.86. This value is below the healthy minimum of 10. It has increased from 1.95 (Mar 24) to 3.86, marking an increase of 1.91.
- For Net Profit Margin (%), as of Mar 25, the value is 3.65. This value is below the healthy minimum of 5. It has increased from 1.92 (Mar 24) to 3.65, marking an increase of 1.73.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -12.07. This value is below the healthy minimum of 8. It has increased from -24.64 (Mar 24) to -12.07, marking an increase of 12.57.
- For Return on Networth / Equity (%), as of Mar 25, the value is -10.15. This value is below the healthy minimum of 15. It has increased from -29.87 (Mar 24) to -10.15, marking an increase of 19.72.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.18. This value is below the healthy minimum of 10. It has increased from 3.56 (Mar 24) to 4.18, marking an increase of 0.62.
- For Return On Assets (%), as of Mar 25, the value is -8.05. This value is below the healthy minimum of 5. It has increased from -21.66 (Mar 24) to -8.05, marking an increase of 13.61.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has decreased from 0.07 (Mar 24) to 0.06, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.77. It has decreased from 0.79 (Mar 24) to 0.77, marking a decrease of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.48. This value is below the healthy minimum of 1.5. It has increased from 1.35 (Mar 24) to 1.48, marking an increase of 0.13.
- For Quick Ratio (X), as of Mar 25, the value is 1.08. This value is within the healthy range. It has increased from 0.93 (Mar 24) to 1.08, marking an increase of 0.15.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.78. This value exceeds the healthy maximum of 8. It has increased from 4.28 (Mar 24) to 8.78, marking an increase of 4.50.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.66. This value is within the healthy range. It has increased from 4.94 (Mar 24) to 5.66, marking an increase of 0.72.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.93. This value is within the healthy range. It has increased from 2.81 (Mar 24) to 3.93, marking an increase of 1.12.
- For Enterprise Value (Cr.), as of Mar 25, the value is 322.19. It has increased from 247.92 (Mar 24) to 322.19, marking an increase of 74.27.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.90. This value exceeds the healthy maximum of 3. It has increased from 3.12 (Mar 24) to 3.90, marking an increase of 0.78.
- For EV / EBITDA (X), as of Mar 25, the value is 55.34. This value exceeds the healthy maximum of 15. It has decreased from 59.41 (Mar 24) to 55.34, marking a decrease of 4.07.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.84. This value exceeds the healthy maximum of 3. It has increased from 3.06 (Mar 24) to 3.84, marking an increase of 0.78.
- For Price / BV (X), as of Mar 25, the value is 3.23. This value exceeds the healthy maximum of 3. It has decreased from 3.71 (Mar 24) to 3.23, marking a decrease of 0.48.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.84. This value exceeds the healthy maximum of 3. It has increased from 3.06 (Mar 24) to 3.84, marking an increase of 0.78.
- For EarningsYield, as of Mar 25, the value is -0.03. This value is below the healthy minimum of 5. It has increased from -0.08 (Mar 24) to -0.03, marking an increase of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Brooks Laboratories Ltd:
- Net Profit Margin: 3.65%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.18% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -10.15% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.93
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.08
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 12.6 (Industry average Stock P/E: 46.05)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 3.65%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Village Kishanpura,. Solan District Himachal Pradesh 174101 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Bhushan Singh Rana | Whole Time Director |
| Mr. Jitendra Pratap Singh | Whole Time Director |
| Mr. Durga Shankar Maity | Whole Time Director |
| Mr. Manav Mahajan | Independent Director |
| Mr. Lalit Mahajan | Independent Director |
| Dr. Usha Singh | Independent Director |
FAQ
What is the intrinsic value of Brooks Laboratories Ltd?
Brooks Laboratories Ltd's intrinsic value (as of 03 February 2026) is ₹78.07 which is 29.68% higher the current market price of ₹60.20, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹177 Cr. market cap, FY2025-2026 high/low of ₹166/58.4, reserves of ₹86 Cr, and liabilities of ₹140 Cr.
What is the Market Cap of Brooks Laboratories Ltd?
The Market Cap of Brooks Laboratories Ltd is 177 Cr..
What is the current Stock Price of Brooks Laboratories Ltd as on 03 February 2026?
The current stock price of Brooks Laboratories Ltd as on 03 February 2026 is ₹60.2.
What is the High / Low of Brooks Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Brooks Laboratories Ltd stocks is ₹166/58.4.
What is the Stock P/E of Brooks Laboratories Ltd?
The Stock P/E of Brooks Laboratories Ltd is 12.6.
What is the Book Value of Brooks Laboratories Ltd?
The Book Value of Brooks Laboratories Ltd is 39.3.
What is the Dividend Yield of Brooks Laboratories Ltd?
The Dividend Yield of Brooks Laboratories Ltd is 0.00 %.
What is the ROCE of Brooks Laboratories Ltd?
The ROCE of Brooks Laboratories Ltd is 9.93 %.
What is the ROE of Brooks Laboratories Ltd?
The ROE of Brooks Laboratories Ltd is 12.2 %.
What is the Face Value of Brooks Laboratories Ltd?
The Face Value of Brooks Laboratories Ltd is 10.0.